Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News: $VRAY Why Lands' End, Audentes Therapeutics, and ViewRay Jumped Today
Tuesday was a bad day on Wall Street, as major benchmarks fell sharply on news from the White House regarding trade. President Trump said that it might be better for the U.S. not to expect a trade deal with China until after the 2020 presidential election, throwing cold water on recent hopes tha...
Read the whole news VRAY - Why Lands' End, Audentes Therapeutics, and ViewRay Jumped Today
News: $VRAY Why ViewRay Stock Is Shooting Higher Today
In response to announcing collaboration deals with Elekta and Medtronic (NYSE: MDT) as well as a common stock offering, shares of ViewRay (NASDAQ: VRAY) , a seller of innovative radiation therapy machines, jumped 31% as of 11:15 a.m. EST on Tuesday. Here are the key terms of the dea...
In case you are interested VRAY - Why ViewRay Stock Is Shooting Higher Today
Company Losses 100 Million Dollars Plus a year from opperations hell the companies revenues are Pathetic 20 Million but cost of revenues is higher then the revenues its self then other expenses is over 33 Million more and they just lowered the companies outlook expects lower revenues and higher cost going forward just did a nasty 86 Million Dollar stock offering expect a Tidal wave of shares going forward market cap is crazy high given the horrible fundamentals of this company this company is a BLOATED POS Who in the hell even buys this trash this is pure garbage YUCK
VRAY is up $1.109 after-hours, might be shorts trying to cover, might also be the Elektra and Medtronics alliances have gotten VRAY some love.....whatever, I'm glad to see it move up.
the only thing I see for stockholders is major dillution
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock to be sold in the offering will be offered by ViewRay. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
https://mma.prnewswire.com/media/560662/ViewRay_Logo.jpg
ViewRay intends to use the net proceeds from the offering for working capital and general corporate purposes, including capital expenditures, research and development expenses, investments, commercial expenses, clinical data generation costs and infrastructure expenses.
Piper Jaffray & Co. is acting as the sole book-running manager for the offering.
ViewRay, Inc. (Nasdaq: VRAY) announced today that it has signed a non-binding memorandum of understanding for collaboration with Elekta AB (Nasdaq: EKTA-B.ST) ("Elekta") to advance the knowledge and use of MR-guided radiation therapy. In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement.
Additionally, ViewRay has signed a non-binding memorandum of understanding with Medtronic (NYSE: MDT) to enter into a clinical collaboration in an area of mutual interest that includes exploring the clinical benefits of the MRIdian MR-guided radiation therapy system. In connection with the collaboration, Medtronic has committed to invest in a minority interest in ViewRay, subject to the terms and conditions set forth in a commitment agreement.
ViewRay's largest shareholder, Fosun International Limited ("Fosun"), has also committed capital up to an amount that would enable it to maintain its current beneficial ownership percentage in ViewRay, subject to the terms and conditions set forth in a commitment agreement.
The investments from Elekta and Medtronic are conditioned upon the consummation of an equity capital raise of at least $75 million.
"We are pleased to announce these important collaborations and investments in ViewRay. Our goal is to concurrently prove the value of MR-guided radiation therapy and strengthen our balance sheet," said Scott Drake, President and CEO of ViewRay. "We are well-positioned to drive MRIdian to standard of care. The ability to see clearly during the procedure, track tumors and soft tissues, and auto-gate the beam is integral to delivering highly precise, personalized medicine."
Collaboration with Elekta
The key objective of the collaboration with Elekta is to advance MR-linac technology and its application as the radiation therapy with superior precision, medical outcomes, and operational cost efficiency. The companies intend to facilitate clinical studies exploring the impact of MR-guided therapy in oncology and work jointly to expand the potential role of MR-guided therapy into other areas that could benefit from the technology. The companies are also exploring initiatives such as the formation of a cooperative group and working on healthcare policy. The collaboration is subject to the execution of definitive documentation.
In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay. Elekta's investment in ViewRay is subject to the terms and conditions set forth in a commitment agreement, including the condition of consummation of an equity capital raise of at least $75 million. In addition, Elekta's investment in ViewRay is subject to an aggregate cap of $36 million.
"We believe that ViewRay and Elekta can work together to drive broad adoption of MR-linacs," said Scott Drake, President and CEO of ViewRay. "We look forward to further promoting this technology to benefit patients worldwide."
"Two companies actively promoting the implementation of the MR-linac technology in the market and collaborating on clinical applications will benefit clinicians and their patients with better and wider treatment options, improved outcomes, and lower costs," said Richard Hausmann, Elekta's President and CEO.
Contact:
News: $VRAY ViewRay® to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference
CLEVELAND , Nov. 20, 2019 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in the 2019 Piper Jaffray 31 st Annual Healthcare Conference in New York, New York . Scott Drake , President and CEO, will give a presentation at 1:30p.m. Eastern T...
Got this from VRAY - ViewRay® to Present at the 2019 Piper Jaffray 31st Annual Healthcare Conference
$VRAY 13D Fosun Intl increases stake to 17.7%
* * $VRAY Video Chart 11-13-19 * *
Link to Video - click here to watch the technical chart video
News: $VRAY 2-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds ViewRay (VRAY) Investors of November 12th Lead Plaintiff Deadline, Encourages Investors with Significant Losses to Contact the Firm
SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2019 / Hagens Berman urges ViewRay, Inc. (NASDAQ:VRAY) investors who have suffered losses in excess of $50,000 to submit their losses now to learn if they qualify to recover their investment losses. Only two days remain until the November 12...
Find out more VRAY - 2-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds ViewRay (VRAY) Investors of November 12th Lead Plaintiff Deadline, Encourages Investors with Significant Losses to Contact the Firm
News: $VRAY 3-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds ViewRay (VRAY) Investors of November 12th Lead Plaintiff Deadline, Encourages Investors with Significant Losses to Contact the Firm
SAN FRANCISCO, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Hagens Berman urges ViewRay, Inc. (NASDAQ: VRAY) investors who have suffered losses in excess of $50,000 to submit their losses now to learn if they qualify to recover their investment losses. The November 12, 2019 lead plaintiff dead...
Read the whole news VRAY - 3-DAY DEADLINE ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds ViewRay (VRAY) Investors of November 12th Lead Plaintiff Deadline, Encourages Investors with Significant Losses to Contact the Firm
News: $VRAY HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds ViewRay (VRAY) Investors of Lead Plaintiff Deadline: Investors Who Have Suffered Significant Losses Encouraged to Contact the Firm Now
Class-action law firm urges VRAY investors who have suffered losses of 50K+ to submit your loss now to learn if they qualify to recover their investment losses. SAN FRANCISCO, CA / ACCESSWIRE / October 26, 2019 / Hagens Berman reminds investors in ViewRay, Inc. (NASDAQ:VRAY)...
In case you are interested VRAY - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds ViewRay (VRAY) Investors of Lead Plaintiff Deadline: Investors Who Have Suffered Significant Losses Encouraged to Contact the Firm Now
* * $VRAY Video Chart 10-15-2019 * *
Link to Video - click here to watch the technical chart video
* * $VRAY Video Chart 10-14-2019 * *
Link to Video - click here to watch the technical chart video
* * $VRAY Video Chart 10-11-2019 * *
Link to Video - click here to watch the technical chart video
News: $VRAY ViewRay Announces Results of the First Prospective Clinical Trial on MR-guided Radiation Treatment for Prostate Cancer Without Implanted Markers
CLEVELAND , Aug. 19, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today the acceptance of publication by the International Journal of Radiation Oncology, Biology and Physics of the first prospective clinical trial of MR-guided radiation therapy (MRgRT) in patients with...
In case you are interested ViewRay Announces Results of the First Prospective Clinical Trial on MR-guided Radiation Treatment for Prostate Cancer Without Implanted Markers
VRAY - Monster Drop. Can It Retrace The Losses?
ViewRay , Inc. engages in the design, manufacture and market magnetic resonance imaging (MRI) system. It develops MRIdian to address the key limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.
P/E Current
-4.03
P/E Ratio (with extraordinary items)
-3.37
SHORT INTEREST
22.51M 07/31/19
Average Recommendation: BUY
Average Target Price: 6.80
* * $VRAY Video Chart 08-16-2019 * *
Link to Video - click here to watch the technical chart video
VRAY - ViewRay, Inc. Buyout territory here. Explains recent positions and insider purchases from CEO.
PT’s $9-11 making this an ideal hospital takeover candidate
* * $VRAY Video Chart 08-12-2019 * *
Link to Video - click here to watch the technical chart video
* * $VRAY Video Chart 08-09-2019 * *
Link to Video - click here to watch the technical chart video
News: $VRAY Leading Medical Physics Meeting to Feature More than 40 Presentations on ViewRay's MRIdian MRI-Guided Radiotherapy
CLEVELAND , July 10, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® System is the focus of more than 40 abstracts selected by the American Association of Physicists in Medicine (AAPM) for presentation during their 2019 Annual Meetin...
In case you are interested Leading Medical Physics Meeting to Feature More than 40 Presentations on ViewRay's MRIdian MRI-Guided Radiotherapy
* * $VRAY Video Chart 05-03-2019 * *
Link to Video - click here to watch the technical chart video
heavy volume 3.3m shares on a no news day
* * $VRAY Video Chart 11-09-18 * *
Link to Video - click here to watch the technical chart video
Viewray (VRAY) Stock Rating Reaffirmed by Cantor Fitzgerald
Posted by ABMN Staff on Oct 3rd, 2018 // No Comments
Viewray logoViewray (NASDAQ:VRAY)‘s stock had its “buy” rating restated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday. They currently have a $13.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 36.84% from the company’s current price.
The analysts wrote, “We reiterate our Overweight rating on shares of VRAY and our 12-month price target of $13. VRAY has succeeded in bringing an MRI linear accelerator (linac) to the market when its larger competitors could not. VRAY’s differentiated technology has the potential to change radiation therapy longer term, but VRAY’s commercial launch is only in its infancy. Positive early clinical data are driving physician interest, but the price of the system comes at a significant premium (~50%) to existing linacs. VRAY, like many small capital equipment companies, comes with a good amount of risk, but we think the momentum is building.””
https://www.americanbankingnews.com/2018/10/03/viewray-vray-stock-rating-reaffirmed-by-cantor-fitzgerald.html
The Veterans Affairs news didn't come from a press release.
https://www.fbo.gov/?s=opportunity&mode=form&id=be1988e5b7865933a08fc60ed4ef441f
ViewRay Technologies Awarded A $6.3M Contract On Sept. 18th By The Dept. Of Veteran Affairs
Load Under $12
Excellent Call
Get ready to see an all time new high, once they release the news they have been holding.
I'm gonna do like the rest of them did and let your silly ass keep talking to your self on this board
Thank you Vray you are my first short... and i kicked your ass with 0.02% gain boooyaaaa 1/4 of 1 percent gain take that slut XD
Vray why are you being like this just go back down where your home is
small support bounce and thats it!!! if you are new get out while you can... this is crashing
VRAY LOADING ZONE ALERT
Company will be turning mad profits and EPS soon enough and the whales will come in mouth's wide open.
Solid business plan, solid product, solid implementation strategy.
Really didn't think I would get this chance! Bought my final 1/3 today. Full on the name now. She is a winner.
I bought more this morning at the drop. My only hesitation is, not with the company, but the inevitable market correction.
Tell me more. Holding on. Must go to 5 for me to get out. Thoughts?
How can anyone predict this will go down from here? Laughable. High RSI? Meaningless. Can stay overbought for a long time.
Important info:
3.7 BILLION dollar market
1100 MRI systems get replaced annually
Imo a 10 bagger.
on the move before earnings. 6% yesterday, 8% today (so far)
Earnings tomorrow after the close.
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
111
|
Created
|
04/05/15
|
Type
|
Free
|
Moderators |
For customer service, call 855.286.8875 toll free. To request a login for the Customer Resource Center, please click here.
4921 Parkview Place
St. Louis, MO 63110
(314) 747-3046
Department of Radiation Oncology
200 UCLA Medical Plaza, Suite B265
Los Angeles, CA 90095
(310) 825-9775
600 Highland Ave.
Madison, WI 53792
(608) 262-5223
MRIdian is a next-generation, MRI-guided radiation therapy system that is comprised of four major components, (i) the MRI system, (ii) the radiation delivery system, (iii) integrated treatment planning and delivery software and (iv) a safety and control system.
MRIdian
MRI System
The MRI system is the component of MRIdian that captures soft tissue images of the patient’s body. To address the technical complications that arise from combining an MRI with a linac, we have designed a proprietary split superconducting magnet that allows treatment through a central gap, eliminating MRI components in the path of the beam. Our MRI system captures and displays live, high-quality images in three planes at two frames per second or in one plane at four frames per second. The images are used to track tissues and control radiation treatment beam delivery.
While other MRI systems in development utilize a high field strength magnet to provide a clearer image, use of higher field strength magnets results in distortions of soft tissue images by up to approximately six millimeters at 1.5 tesla and unfavorable dose distribution distortions, which are unacceptable for delivering accurate radiation therapy. We have engineered our MRI system to be able to produce clear images using a low field strength 0.35 tesla magnet which enables us to avoid the image and dose distortions that are a result of using a higher field strength magnet. In addition, MRIdian’s 0.35 tesla field strength prevents heating of the patient during uninterrupted imaging, which could occur in a higher field strength magnet requiring the imaging to be discontinued or interrupted.
MRI System
Radiation Delivery System
Radiation is delivered from three Cobalt-60 radiation therapy heads symmetrically mounted on a rotating ring gantry, providing full 360 degree coverage and simultaneous dose delivery, as opposed to prior Cobalt-60 systems that have historically been limited by imprecise radiation dose applications. Each head is equipped with a double focused multi-leaf collimator, designed to overcome the wide-beam edge of previous-generation Cobalt-60 systems and shape the beam for precision radiation therapy treatments. It allows the delivery of treatment plans for 3D-CRT, IMRT and SBRT that are clinically equivalent to those produced on the most advanced linear accelerators available today. Stereotactic procedures are possible with a positioning accuracy of less than one millimeter. Cobalt-60 is used because it does not create any radio frequency which interferes with the MRI.
Comparison of Previous-Generation Cobalt Beam to ViewRay Cobalt Beam
Integrated Treatment Planning and Delivery Software
Our treatment planning and delivery software can create treatment plans and manage the treatment delivery process. It is designed to create optimized 3D-CRT, IMRT and SBRT plans for delivery on MRIdian.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |